DT&CRO Co Ltd
383930
Company Profile
Business description
DT&CRO Co Ltd conducts a series of consigned research, from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics and medical devices, to analysis, bioactivity, clinical trials, and licensing consulting. provided as a service.
Contact
28, Baengnyeong-ro 20beon-gil
2nd, 3rd, 4th floor, Na-dong
Cheoin-gu, Gyeonggi-do (Yubang-dong)
Yongin-si17042
KORT: +82 313222400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
345
Stocks News & Analysis
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
stocks
New production imminent for undervalued ASX gas play
LNG project receives first commissioning gas.
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,324.60 | 40.80 | 0.44% |
| CAC 40 | 8,189.49 | 15.29 | 0.19% |
| DAX 40 | 24,208.65 | 377.66 | 1.58% |
| Dow JONES (US) | 46,396.40 | 205.79 | 0.45% |
| FTSE 100 | 9,400.59 | 46.02 | 0.49% |
| HKSE | 25,858.83 | 611.73 | 2.42% |
| NASDAQ | 22,851.45 | 171.47 | 0.76% |
| Nikkei 225 | 49,185.50 | 1,603.35 | 3.37% |
| NZX 50 Index | 13,344.96 | 55.75 | 0.42% |
| S&P 500 | 6,703.42 | 39.41 | 0.59% |
| S&P/ASX 200 | 9,031.90 | 43.70 | 0.49% |
| SSE Composite Index | 3,863.89 | 24.14 | 0.63% |